Modulation of asthmatic airway inflammation by activation of epithelial proteinase activated receptors

通过激活上皮蛋白酶激活受体调节哮喘气道炎症

• 批准号: nhmrc : 114242
• 负责人: Prof Gary Anderson
• 金额: $ 12.6万
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2000
• 资助国家: 澳大利亚
• 起止时间: 2000-01-01 至 2002-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/modulation-asthmatic-airway-activated-receptors/101161
• 关键词: Modulation; asthmatic; airway; inflammation; activation

Children and adults feel the symptoms of asthma because their airways close up too easily. We have discovered a new mechanism that the healthy lung uses to keep airways open. The epithelial cells which line the airway release an enzyme that cuts of a small part of another protein, called a PAR receptor, that sits on the same cell. When this happens the epithelial cell releases relaxing substances from their lower surface. The relaxing substances keep the airways open. This grant application is designed to test whether the relaxing system also stops the airways from developing inflammation. If the relaxing system does this we will be able to use the knowlege we have that lets us activate the PAR receptors artificially to design new types of drugs. These drugs would be better than existing asthma drugs because they would prevent inflammation and relax the airways at the same time. These drugs could also be useful in other lung diseases such as chronic bronchitis.

儿童和成人之所以会出现哮喘症状，是因为他们的呼吸道太容易闭合。我们发现了健康肺部用来保持呼吸道畅通的新机制。气道内壁的上皮细胞会释放一种酶，该酶可以切割位于同一细胞上的另一种蛋白质（称为 PAR 受体）的一小部分。当这种情况发生时，上皮细胞从其下表面释放松弛物质。放松物质保持呼吸道畅通。该拨款申请旨在测试放松系统是否也能阻止气道发炎。如果放松系统能够做到这一点，我们将能够利用我们所掌握的知识，人工激活 PAR 受体来设计新型药物。这些药物比现有的哮喘药物更好，因为它们可以同时预防炎症和放松气道。这些药物也可用于治疗慢性支气管炎等其他肺部疾病。